{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:31:27Z","timestamp":1794317487578,"version":"4.9.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dasatinib (DSB) is a second-generation tyrosine kinase inhibitor widely used for treating chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph\u2009+\u2009ALL). Though clinically effective, DSB has some pharmacokinetic drawbacks evidenced by rapid systemic clearance, low oral bioavailability, and poor aqueous solubility requiring high doses for therapeutic action. Novel formulation strategies like solid dispersions, liposomal formulations, and PEGylated and hybrid nanoparticles enhance DSB's pharmacokinetic and pharmacodynamic profiles by enhancing drug solubility, stability, and controlled release. In addition, through these targeted drug-delivery systems based on ligand-functionalized nanoparticles and antibody\u2013drug conjugates-the tumor-targeted DSB is allowed selective accumulation at the tumor site, causing fewer off-target effects and lessening systemic toxicity while maximizing effectiveness. These approaches are geared toward utilizing nanotechnology to improve intracellular drug uptake and extend the circulation time to optimize antitumor efficacy. Overall, those advances in drug delivery systems could greatly boost the therapeutic efficacy of DSB by providing better bioavailability, controlled release, and targeted distribution. Such advances would increase treatment success in CML and Ph\u2009+\u2009ALL and expand DSB's potential clinical applications toward other malignancies. Research concerning the delivery of DSB with nanocarriers and ligand-mediated targeting strategies should bear further fruits to augment DSB therapy in oncology.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1208\/s12249-025-03130-7","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:47:39Z","timestamp":1747154859000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Dasatinib Pharmacokinetics and Advanced Nanocarrier Strategies: from Systemic Limitations to Targeted Success"],"prefix":"10.1208","volume":"26","author":[{"given":"Mahesha","family":"Keerikkadu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragathi Devanand","family":"Bangera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamshi Krishna","family":"Tippavajhala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6339-2836","authenticated-orcid":false,"given":"Mahalaxmi","family":"Rathnanand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"3130_CR1","doi-asserted-by":"crossref","unstructured":"Fauziya, Gupta A, Nadaf A, Ahmad S, Hasan N, Imran M, et al. Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies. Med Oncol. 2023;40:173.","DOI":"10.1007\/s12032-023-02018-5"},{"key":"3130_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-021-01117-y","volume":"14","author":"H Zhang","year":"2021","unstructured":"Zhang H, Hu Y, Shao M, Teng X, Jiang P, Wang X, et al. Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion. J Hematol OncolJ Hematol Oncol. 2021;14:113.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"3130_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3390\/pharmaceutics15030917","volume":"15","author":"A Rodr\u00edguez-Agust\u00edn","year":"2023","unstructured":"Rodr\u00edguez-Agust\u00edn A, Casanova V, Grau-Exp\u00f3sito J, S\u00e1nchez-Palomino S, Alcam\u00ed J, Climent N. Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer HIV Infection and Aging. Pharmaceutics. 2023;15:917.","journal-title":"Pharmaceutics"},{"key":"3130_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s00044-022-03011-9","volume":"32","author":"SK De","year":"2023","unstructured":"De SK. Asciminib: first FDA approved allosteric inhibitor of BCR-ABL1 for the treatment of chronic myeloid leukemia. Med Chem Res. 2023;32:424\u201333.","journal-title":"Med Chem Res"},{"key":"3130_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/13543784.2023.2179481","volume":"32","author":"Y Wang","year":"2023","unstructured":"Wang Y, Xue J, Su Z, Cui Y, Liu G, Yang W, et al. Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects. Expert Opin Investig Drugs. 2023;32:263\u201370.","journal-title":"Expert Opin Investig Drugs"},{"key":"3130_CR6","doi-asserted-by":"publisher","unstructured":"He S, Bian J, Shao Q, Zhang Y, Hao X, Luo X, et al. Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics. Front Pharmacol. 2021;12. Available from: https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/https:\/\/doi.org\/10.3389\/fphar.2021.797881\/full.  Cited 2025 Feb 10.","DOI":"10.3389\/fphar.2021.797881\/full"},{"key":"3130_CR7","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","volume":"59","author":"D Lev\u00eaque","year":"2020","unstructured":"Lev\u00eaque D, Becker G, Bilger K, Natarajan-Am\u00e9 S. Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib. Clin Pharmacokinet. 2020;59:849\u201356.","journal-title":"Clin Pharmacokinet"},{"key":"3130_CR8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/ajh.26689","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, et al. Low-dose dasatinib 50 mg\/day versus standard-dose dasatinib 100 mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022;97:1413\u20138.","journal-title":"Am J Hematol"},{"key":"3130_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023;8:1\u201327.","journal-title":"Signal Transduct Target Ther"},{"key":"3130_CR10","doi-asserted-by":"publisher","unstructured":"Cheng F, Xu Q, Li Q, Cui Z, Li W, Zeng F. Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies. Front Oncol. 2023;13. Available from: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/https:\/\/doi.org\/10.3389\/fonc.2023.1113462\/full.  Cited 2024 Nov 18.","DOI":"10.3389\/fonc.2023.1113462\/full"},{"key":"3130_CR11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3390\/jpm11060559","volume":"11","author":"F Bahman","year":"2021","unstructured":"Bahman F, Pittal\u00e0 V, Haider M, Greish K. Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer. J Pers Med. 2021;11:559.","journal-title":"J Pers Med"},{"key":"3130_CR12","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1021\/acs.iecr.2c00370","volume":"62","author":"S Tajik","year":"2023","unstructured":"Tajik S, Afshar AA, Shamsaddini S, Askari MB, Dourandish Z, Garkani Nejad F, et al. Fe3O4@MoS2\/rGO Nanocomposite\/Ionic Liquid Modified Carbon Paste Electrode for Electrochemical Sensing of Dasatinib in the Presence of Doxorubicin. Ind Eng Chem Res. 2023;62:4473\u201380.","journal-title":"Ind Eng Chem Res"},{"key":"3130_CR13","doi-asserted-by":"crossref","unstructured":"de Oliveira VA, Negreiros HA, de Sousa IGB, Farias Mendes LK, Alves Damaceno Do Lago JP, Alves de Sousa A. et al. Application of nanoformulations as a strategy to optimize chemotherapeutic treatment of glioblastoma: a systematic review. J Toxicol Environ Health Part B. 2024;27(4):131-52.","DOI":"10.1080\/10937404.2024.2326679"},{"key":"3130_CR14","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1038\/s41467-021-25453-2","volume":"12","author":"EJ Novais","year":"2021","unstructured":"Novais EJ, Tran VA, Johnston SN, Darris KR, Roupas AJ, Sessions GA, et al. Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice. Nat Commun. 2021;12:5213.","journal-title":"Nat Commun"},{"key":"3130_CR15","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3390\/ijms25020786","volume":"25","author":"M Jamro\u017cy","year":"2024","unstructured":"Jamro\u017cy M, Kud\u0142acik-Kramarczyk S, Drabczyk A, Krzan M. Advanced drug carriers: a review of selected protein, polysaccharide, and lipid drug delivery platforms. Int J Mol Sci. 2024;25:786.","journal-title":"Int J Mol Sci"},{"key":"3130_CR16","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Fo\u00e0","year":"2024","unstructured":"Fo\u00e0 R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, et al. Long-term results of the dasatinib-blinatumomab protocol for adult philadelphia-positive all. J Clin Oncol. 2024;42:881\u20135.","journal-title":"J Clin Oncol"},{"key":"3130_CR17","doi-asserted-by":"publisher","first-page":"118785","DOI":"10.1016\/j.ijpharm.2019.118785","volume":"573","author":"Y Yin","year":"2020","unstructured":"Yin Y, Yuan X, Gao H, Yang Q. Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy. Int J Pharm. 2020;573:118785.","journal-title":"Int J Pharm"},{"key":"3130_CR18","unstructured":"Cheng Y, Zhang J, Mu W, Ye S, Cheng J, Zhu L, et al. Dasatinib-resistant universal CAR-T cells proliferate in the presence of host immune cells and exhibit antitumor activity. Mol Ther. 2025;0. Available from: https:\/\/www.cell.com\/molecular-therapy-family\/molecular-therapy\/abstract\/S1525-0016(25)00102-9.  Cited 2025 Feb 28."},{"key":"3130_CR19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41568-024-00723-5","volume":"24","author":"N Wellhausen","year":"2024","unstructured":"Wellhausen N, Baek J, Gill SI, June CH. Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance. Nat Rev Cancer. 2024;24:614\u201328.","journal-title":"Nat Rev Cancer"},{"key":"3130_CR20","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.therap.2021.10.010","volume":"77","author":"A Shinde","year":"2022","unstructured":"Shinde A, Panchal K, Katke S, Paliwal R, Chaurasiya A. Tyrosine kinase inhibitors as next generation oncological therapeutics: Current strategies, limitations and future perspectives. Therapies. 2022;77:425\u201343.","journal-title":"Therapies"},{"key":"3130_CR21","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1039\/D4CC05851H","volume":"61","author":"S Wang","year":"2025","unstructured":"Wang S, Li C, Zhang J, Ma K, Zhang W, Gao Y, et al. Uniform and size-tunable dasatinib nanoemulsions synthesized by a high-throughput microreactor for enhanced temperature stability. Chem Commun. 2025;61:3524\u20137.","journal-title":"Chem Commun"},{"key":"3130_CR22","doi-asserted-by":"publisher","first-page":"101966","DOI":"10.1016\/j.scp.2025.101966","volume":"44","author":"PP Bang","year":"2025","unstructured":"Bang PP, Bhatt HG. Sustainable quantitative analysis of Dasatinib Monohydrate using green RP- and NP-HPTLC methods in API and formulation with greenness evaluation by AGREE tool. Sustain Chem Pharm. 2025;44:101966.","journal-title":"Sustain Chem Pharm"},{"key":"3130_CR23","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/s41375-023-01900-5","volume":"37","author":"S Yoshimura","year":"2023","unstructured":"Yoshimura S, Panetta JC, Hu J, Li L, Gocho Y, Du G, et al. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia. Leukemia. 2023;37:1194\u2013203.","journal-title":"Leukemia"},{"key":"3130_CR24","doi-asserted-by":"publisher","first-page":"117709","DOI":"10.1016\/j.biopha.2024.117709","volume":"181","author":"K Kawashima","year":"2024","unstructured":"Kawashima K, Ikemura K, Takemura M, Toyozumi Y, Okuda M. Febuxostat enhances the efficacy of dasatinib by inhibiting ATP-binding cassette subfamily G member 2 (ABCG2) in chronic myeloid leukemia cells. Biomed Pharmacother. 2024;181:117709.","journal-title":"Biomed Pharmacother"},{"key":"3130_CR25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s43440-024-00600-w","volume":"76","author":"M Kaul","year":"2024","unstructured":"Kaul M, Sanin AY, Shi W, Janiak C, Kahlert UD. Nanoformulation of dasatinib cannot overcome therapy resistance of pancreatic cancer cells with low LYN kinase expression. Pharmacol Rep. 2024;76:793\u2013806.","journal-title":"Pharmacol Rep"},{"key":"3130_CR26","doi-asserted-by":"publisher","first-page":"114710","DOI":"10.1016\/j.bcp.2021.114710","volume":"192","author":"N B\u00fck\u00fcm","year":"2021","unstructured":"B\u00fck\u00fcm N, Novotn\u00e1 E, Morell A, \u017delazkov\u00e1 J, La\u0161tovi\u010dkov\u00e1 L, \u010cerm\u00e1kov\u00e1 L, et al. Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib. Biochem Pharmacol. 2021;192:114710.","journal-title":"Biochem Pharmacol"},{"key":"3130_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12012-019-09538-5","volume":"20","author":"H Izumi-Nakaseko","year":"2020","unstructured":"Izumi-Nakaseko H, Fujiyoshi M, Hagiwara-Nagasawa M, Goto A, Chiba K, Kambayashi R, et al. Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors. Cardiovasc Toxicol. 2020;20:58\u201370.","journal-title":"Cardiovasc Toxicol"},{"key":"3130_CR28","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41375-024-02145-6","volume":"38","author":"H Flygt","year":"2024","unstructured":"Flygt H, S\u00f6derlund S, Richter J, Saussele S, Koskenvesa P, Stenke L, et al. Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib \u2013 interim results from the DAstop2 trial. Leukemia. 2024;38:781\u20137.","journal-title":"Leukemia"},{"key":"3130_CR29","doi-asserted-by":"publisher","unstructured":"Cheng M, Yang F, Liu J, Yang D, Zhang S, Yu Y, et al. Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies. Front Cardiovasc Med. 2021;8. Available from: https:\/\/www.frontiersin.org\/journals\/cardiovascular-medicine\/articles\/https:\/\/doi.org\/10.3389\/fcvm.2021.758010\/full.  Cited 2025 Feb 5.","DOI":"10.3389\/fcvm.2021.758010\/full"},{"key":"3130_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.therap.2021.12.002","volume":"77","author":"S Bouchet","year":"2022","unstructured":"Bouchet S, Molimard M. Pharmacokinetics and therapeutic drug monitoring of anticancer protein\/kinase inhibitors. Therapies. 2022;77:157\u201370.","journal-title":"Therapies"},{"key":"3130_CR31","doi-asserted-by":"publisher","unstructured":"Andersson P, Brisander M, Liljebris C, Jesson G, Lennern\u00e4s H. Severe Impact of Omeprazole Timing on pH-Sensitive Dasatinib Absorption: Unveiling Substantial Drug\u2013Drug Interaction. J Clin Pharmacol.;n\/a. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1002\/jcph.6173.  Cited 2025 Feb 4.","DOI":"10.1002\/jcph.6173"},{"key":"3130_CR32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/bjh.19058","volume":"203","author":"MA Perusini","year":"2023","unstructured":"Perusini MA, Novitzky-Basso I, Atenafu EG, Forrest D, Bence-Bruckler I, Savoie L, et al. Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study. Br J Haematol. 2023;203:781\u201391.","journal-title":"Br J Haematol"},{"key":"3130_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.7150\/ijms.102088","volume":"22","author":"K Alhazzani","year":"2025","unstructured":"Alhazzani K, Alqarni NN, Aljerian K, Raish M, Aljuffali L, Alshehri S, et al. Naringenin Mitigates Dasatinib-Induced Kidney Damage by Modulating Antioxidant Defense, Inflammation, and Apoptosis Pathways. Int J Med Sci. 2025;22:110\u201320.","journal-title":"Int J Med Sci"},{"key":"3130_CR34","doi-asserted-by":"publisher","first-page":"113858","DOI":"10.1016\/j.colsurfb.2024.113858","volume":"237","author":"N Soomherun","year":"2024","unstructured":"Soomherun N, Kreua-ongarjnukool N, Niyomthai ST, Chumnanvej S. Lipid-Polymer hybrid nanoparticles synthesized via lipid-based surface engineering for a robust drug delivery platform. Colloids Surf B Biointerfaces. 2024;237:113858.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3130_CR35","doi-asserted-by":"publisher","first-page":"123784","DOI":"10.1016\/j.ijpharm.2024.123784","volume":"651","author":"A Mehandole","year":"2024","unstructured":"Mehandole A, Mahajan S, Aalhate M, Kumar R, Maji I, Gupta U, et al. Dasatinib loaded mucoadhesive lecithin-chitosan hybrid nanoparticles for its augmented oral delivery, in-vitro efficacy and safety. Int J Pharm. 2024;651:123784.","journal-title":"Int J Pharm"},{"key":"3130_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jconrel.2024.10.001","volume":"376","author":"J Lei","year":"2024","unstructured":"Lei J, Wang L, Yang C, Li D, Zhang J, Ma J, et al. Dasatinib and erianin co-loaded ion-responsive in-situ hydrogel for effective treatment of corneal neovascularization. J Controlled Release. 2024;376:94\u2013107.","journal-title":"J Controlled Release"},{"key":"3130_CR37","doi-asserted-by":"crossref","unstructured":"Patel M, Patel P, Vyas B. Hyaluronic Acid Conjugated Liposomes for Targeted Delivery of Ibrutinib: In Vitro, Cell Line, and In Vivo Assessment. BioNanoScience. 2025;15:240.","DOI":"10.1007\/s12668-025-01853-2"},{"key":"3130_CR38","doi-asserted-by":"crossref","unstructured":"Soghrati S, Varshosaz J, Rostami M, Mirian M. Co-delivery of dasatinib and miR-30a by liposomes targeting neuropilin-1 receptors for triple-negative breast cancer therapy. J Mater Chem B. 2025; Available from: https:\/\/pubs.rsc.org\/en\/content\/articlelanding\/2025\/tb\/d4tb02222j.  Cited 2025 Jan 17.","DOI":"10.1039\/D4TB02222J"},{"key":"3130_CR39","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s13204-024-03057-8","volume":"14","author":"M Nannan","year":"2024","unstructured":"Nannan M, Venkatabalasubramanian S. Microbubble-based liposomal delivery of dasatinib and COL11A1siRNA for enhanced combination therapy against lung adenocarcinoma. Appl Nanosci. 2024;14:931\u201341.","journal-title":"Appl Nanosci"},{"key":"3130_CR40","doi-asserted-by":"publisher","first-page":"102063","DOI":"10.1016\/j.jsps.2024.102063","volume":"32","author":"R Alfaraj","year":"2024","unstructured":"Alfaraj R, Hababah S, Eltayb EK, Alqahtani FY, Aleanizy FS. Isotretinoin self-nano-emulsifying drug delivery system: Preparation, optimization and antibacterial evaluation. Saudi Pharm J. 2024;32:102063.","journal-title":"Saudi Pharm J"},{"key":"3130_CR41","first-page":"749","volume":"15","author":"MA Mohd Ateeq","year":"2024","unstructured":"Mohd Ateeq MA, Mahajan S, Saren BN, Aalhate M, Singh H, Chatterjee E, et al. Solid Self Nano-Emulsifying Drug Delivery System of Dasatinib: Optimization, In-vitro. Ex-vivo and In-vivo assessment Ther Deliv. 2024;15:749\u201368.","journal-title":"Ex-vivo and In-vivo assessment Ther Deliv"},{"key":"3130_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2025.106870","volume":"107","author":"DA Eltahan","year":"2025","unstructured":"Eltahan DA, Eid RK, Ashmawy SM, El Maghraby GM. Nanoemulsion for enhanced absorption and anti-tumor activity of dasatinib. J Drug Deliv Sci Technol. 2025;107: 106870.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3130_CR43","doi-asserted-by":"crossref","unstructured":"Bangera PD, Shukla E, Kara DD, Roychowdhury R, Keerikkadu M, Tippavajhala VK, et al. DEVELOPMENT AND ASSESSMENT OF A SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEM FOR ENHANCED SOLUBILITY OF DASATINIB. Int J Appl Pharm. 2025;123\u201332.","DOI":"10.22159\/ijap.2025v17i1.52404"},{"key":"3130_CR44","doi-asserted-by":"publisher","first-page":"125007","DOI":"10.1016\/j.ijpharm.2024.125007","volume":"668","author":"D Mageshvaran","year":"2025","unstructured":"Mageshvaran D, Yadav S, Yadav V, Kuche K, Katari O, Jain S. Enhancing oral bioavailability of dasatinib via supersaturable SNEDDS: Investigation of precipitation inhibition and IVIVC through in-vitro lipolysis-permeation model. Int J Pharm. 2025;668:125007.","journal-title":"Int J Pharm"},{"key":"3130_CR45","doi-asserted-by":"crossref","unstructured":"Arcos Rosero WA, Bueno Barbezan A, Daruich de Souza C, Chuery Martins Rostelato ME. Review of Advances in Coating and Functionalization of Gold Nanoparticles: From Theory to Biomedical Application. Pharmaceutics. 2024;16:255.","DOI":"10.3390\/pharmaceutics16020255"},{"key":"3130_CR46","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/03639045.2017.1402919","volume":"44","author":"SKR Adena","year":"2018","unstructured":"Adena SKR, Upadhyay M, Vardhan H, Mishra B. Development, optimization, and in vitro characterization of dasatinib-loaded PEG functionalized chitosan capped gold nanoparticles using Box-Behnken experimental design. Drug Dev Ind Pharm. 2018;44:493\u2013501.","journal-title":"Drug Dev Ind Pharm"},{"key":"3130_CR47","doi-asserted-by":"publisher","first-page":"213591","DOI":"10.1016\/j.bioadv.2023.213591","volume":"154","author":"M Khorshid","year":"2023","unstructured":"Khorshid M, Varshosaz J, Rostami M, Haghiralsadat F, Akbari V, Khorshid P. Anti HER-2 aptamer functionalized gold nanoparticles of dasatinib for targeted chemo-radiotherapy in breast cancer cells. Biomater Adv. 2023;154:213591.","journal-title":"Biomater Adv"},{"key":"3130_CR48","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.3390\/ijms25073645","volume":"25","author":"X Wang","year":"2024","unstructured":"Wang X, Li D, Li G, Chen J, Yang Y, Bian L, et al. Enhanced Therapeutic Potential of Hybrid Exosomes Loaded with Paclitaxel for Cancer Therapy. Int J Mol Sci. 2024;25:3645.","journal-title":"Int J Mol Sci"},{"key":"3130_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"L Chen","year":"2021","unstructured":"Chen L, Hong W, Ren W, Xu T, Qian Z, He Z. Recent progress in targeted delivery vectors based on biomimetic nanoparticles. Signal Transduct Target Ther. 2021;6:1\u201325.","journal-title":"Signal Transduct Target Ther"},{"key":"3130_CR50","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1080\/21691401.2023.2264358","volume":"51","author":"X Zhou","year":"2023","unstructured":"Zhou X, Zhuang Y, Liu X, Gu Y, Wang J, Shi Y, et al. Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy. Artif Cells Nanomedicine Biotechnol. 2023;51:532\u201346.","journal-title":"Artif Cells Nanomedicine Biotechnol"},{"key":"3130_CR51","doi-asserted-by":"publisher","first-page":"117248","DOI":"10.1016\/j.biopha.2024.117248","volume":"178","author":"F Soltanmohammadi","year":"2024","unstructured":"Soltanmohammadi F, Gharehbaba AM, Zangi AR, Adibkia K, Javadzadeh Y. Current knowledge of hybrid nanoplatforms composed of exosomes and organic\/inorganic nanoparticles for disease treatment and cell\/tissue imaging. Biomed Pharmacother. 2024;178:117248.","journal-title":"Biomed Pharmacother"},{"key":"3130_CR52","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12668-024-01778-2","volume":"15","author":"K Janakiraman","year":"2025","unstructured":"Janakiraman K, Sethuraman V, Jayaraj G. A Review on Relevance of Nanosomes in Contemporary Therapeutics: Innovative Approach to Drug Delivery. BioNanoScience. 2025;15:191.","journal-title":"BioNanoScience"},{"key":"3130_CR53","doi-asserted-by":"publisher","first-page":"102147","DOI":"10.1016\/j.nantod.2024.102147","volume":"55","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Oz Y, Gu Y, Ahamad N, Shariati K, Chevalier J, et al. Rational design of polymeric micelles for targeted therapeutic delivery. Nano Today. 2024;55:102147.","journal-title":"Nano Today"},{"key":"3130_CR54","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.ijbiomac.2022.12.111","volume":"229","author":"H Vakilzadeh","year":"2023","unstructured":"Vakilzadeh H, Varshosaz J, Dinari M, Mirian M, Hajhashemi V, Shamaeizadeh N, et al. Smart redox-sensitive micelles based on chitosan for dasatinib delivery in suppressing inflammatory diseases. Int J Biol Macromol. 2023;229:696\u2013712.","journal-title":"Int J Biol Macromol"},{"key":"3130_CR55","doi-asserted-by":"publisher","first-page":"e56376","DOI":"10.1002\/app.56376","volume":"142","author":"SV Menon","year":"2025","unstructured":"Menon SV, Thakore S, Verma A, Dhadda S, Chinnathambi A, Alharbi SA, et al. Facile fabrication of dasatinib laden multifunctional polymeric micelles: Evaluation of anti-proliferative and apoptotic activities in human cancer cells. J Appl Polym Sci. 2025;142:e56376.","journal-title":"J Appl Polym Sci"},{"key":"3130_CR56","doi-asserted-by":"publisher","first-page":"103913","DOI":"10.1016\/j.drudis.2024.103913","volume":"29","author":"E Pardhi","year":"2024","unstructured":"Pardhi E, Vasave R, Srivastava V, Yadav R, Mehra NK. Nanocrystal technologies in biomedical science: From the bench to the clinic. Drug Discov Today. 2024;29:103913.","journal-title":"Drug Discov Today"},{"key":"3130_CR57","doi-asserted-by":"publisher","first-page":"105823","DOI":"10.1016\/j.jtice.2024.105823","volume":"167","author":"F Yuan","year":"2025","unstructured":"Yuan F, Sun Y, Guo J, Wei Y, Wang S, Zhao S, et al. Scale-up microreactor coupling binary surfactants for high-throughput preparation of flaky dasatinib nanocrystals. J Taiwan Inst Chem Eng. 2025;167:105823.","journal-title":"J Taiwan Inst Chem Eng"},{"key":"3130_CR58","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/pharmaceutics14010197","volume":"14","author":"C Wang","year":"2022","unstructured":"Wang C, Wang M, Chen P, Wang J, Le Y. Dasatinib Nanoemulsion and Nanocrystal for Enhanced Oral Drug Delivery. Pharmaceutics. 2022;14:197.","journal-title":"Pharmaceutics"},{"key":"3130_CR59","doi-asserted-by":"publisher","first-page":"e55610","DOI":"10.1002\/app.55610","volume":"141","author":"K Soka\u010d","year":"2024","unstructured":"Soka\u010d K, Priselec P, Bara\u010d J, Bafti A, Taradi F, \u017di\u017eek K. Investigating the effect of polyvinylpyrrolidone matrix on surface characteristics and dissolution rate of anticancer drug dasatinib. J Appl Polym Sci. 2024;141:e55610.","journal-title":"J Appl Polym Sci"},{"key":"3130_CR60","doi-asserted-by":"publisher","first-page":"100358","DOI":"10.1016\/j.mtbio.2022.100358","volume":"16","author":"W Xu","year":"2022","unstructured":"Xu W, Ye C, Qing X, Liu S, Lv X, Wang W, et al. Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy. Mater Today Bio. 2022;16:100358.","journal-title":"Mater Today Bio"},{"key":"3130_CR61","doi-asserted-by":"publisher","first-page":"107827","DOI":"10.1016\/j.cclet.2022.107827","volume":"34","author":"J Zuo","year":"2023","unstructured":"Zuo J, Gao X, Xiao J, Cheng Y. Carrier-free supramolecular nanomedicines assembled by small-molecule therapeutics for cancer treatment. Chin Chem Lett. 2023;34:107827.","journal-title":"Chin Chem Lett"},{"key":"3130_CR62","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10522-024-10103-z","volume":"25","author":"K Takaya","year":"2024","unstructured":"Takaya K, Kishi K. Combined dasatinib and quercetin treatment contributes to skin rejuvenation through selective elimination of senescent cells in vitro and in vivo. Biogerontology. 2024;25:691\u2013704.","journal-title":"Biogerontology"},{"key":"3130_CR63","first-page":"806","volume":"19","author":"RA Baghdadi","year":"2024","unstructured":"Baghdadi RA, Abdalla AN, Abourehab MAS, Tulbah AS. Evaluation of the effects of a dasatinib-containing, self-emulsifying, drug delivery system on HT29 and SW420 human colorectal carcinoma cells, and MCF7 human breast adenocarcinoma cells. J Taibah Univ Med Sci. 2024;19:806\u201315.","journal-title":"J Taibah Univ Med Sci"},{"key":"3130_CR64","doi-asserted-by":"publisher","unstructured":"Paul M, Itoo AM, Ghosh B, Biswas S. Current trends in the use of human serum albumin for drug delivery in cancer. Expert Opin Drug Deliv. 2022; Available from: https:\/\/www.tandfonline.com\/doi\/abs\/https:\/\/doi.org\/10.1080\/17425247.2022.2134341.  Cited 2025 Feb 28.","DOI":"10.1080\/17425247.2022.2134341"},{"key":"3130_CR65","doi-asserted-by":"publisher","first-page":"106999","DOI":"10.1016\/j.ejps.2024.106999","volume":"206","author":"JK Koehler","year":"2025","unstructured":"Koehler JK, Schmager S, Schnur J, Gedda L, Edwards K, Heerklotz H, et al. Novel thermosensitive small multilamellar lipid nanoparticles with promising release characteristics made by dual centrifugation. Eur J Pharm Sci. 2025;206:106999.","journal-title":"Eur J Pharm Sci"},{"key":"3130_CR66","doi-asserted-by":"publisher","unstructured":"Aly GA, Sabra SA, Haroun M, Helmy MW, Moussa N. Bovine serum albumin nanoparticles encapsulating Dasatinib and Celecoxib for oral cancer: Preparation, characterization, and in-vitro evaluation. Naunyn Schmiedebergs Arch Pharmacol. 2025; Available from: https:\/\/doi.org\/10.1007\/s00210-025-03829-1.  Cited 2025 Feb 28.","DOI":"10.1007\/s00210-025-03829-1"},{"key":"3130_CR67","doi-asserted-by":"publisher","first-page":"120226","DOI":"10.1016\/j.ijpharm.2021.120226","volume":"596","author":"Q Li","year":"2021","unstructured":"Li Q, Qian X, Li HY, Lai KL, Gao Q, Lee WYT. Safety assessment of polymeric micelles as an ophthalmic drug delivery system for intravitreal administration of dasatinib. Int J Pharm. 2021;596:120226.","journal-title":"Int J Pharm"},{"key":"3130_CR68","doi-asserted-by":"publisher","first-page":"112436","DOI":"10.1016\/j.microc.2024.112436","volume":"208","author":"Y Zhong","year":"2025","unstructured":"Zhong Y, Bao T, Yin X, Deng Q, Zhang Y, Wu T, et al. pH-Sensitive blue-green dual-emission carbon dots for dasatinib detection. Microchem J. 2025;208:112436.","journal-title":"Microchem J"},{"key":"3130_CR69","doi-asserted-by":"publisher","unstructured":"Shaikh S, Chary PS, Mehra NK. Tyrosine Kinase Inhibitor Lenvatinib Based Nano Formulations and Cutting-Edge Scale-Up Technologies in revolutionizing Cancer Therapy. ACS Appl Bio Mater. 2025; Available from: https:\/\/doi.org\/10.1021\/acsabm.4c01527.  Cited 2025 Feb 28.","DOI":"10.1021\/acsabm.4c01527"},{"key":"3130_CR70","doi-asserted-by":"publisher","first-page":"116445","DOI":"10.1016\/j.biopha.2024.116445","volume":"173","author":"Q Ye","year":"2024","unstructured":"Ye Q, Gui C, Jin D, Zhang J, Zhang J, Ma N, et al. Synergistic effect of cannabidiol with dasatinib on lung cancer by SRC\/PI3K\/AKT signal pathway. Biomed Pharmacother. 2024;173:116445.","journal-title":"Biomed Pharmacother"},{"key":"3130_CR71","doi-asserted-by":"publisher","first-page":"124672","DOI":"10.1016\/j.ijpharm.2024.124672","volume":"665","author":"T Kanp","year":"2024","unstructured":"Kanp T, Dhuri A, Aalhate M, Mahajan S, Munagalasetty S, Kumar Sah S, et al. Manifesting the Dasatinib-gallic acid co-amorphous system to augment anticancer potential: Physicochemical characterization, in silico molecular simulation, ex vivo permeability, and in vitro efficacy. Int J Pharm. 2024;665:124672.","journal-title":"Int J Pharm"},{"key":"3130_CR72","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.3390\/pharmaceutics14112450","volume":"14","author":"S Dharani","year":"2022","unstructured":"Dharani S, Mohamed EM, Khuroo T, Rahman Z, Khan MA. Formulation Characterization and Pharmacokinetic Evaluation of Amorphous Solid Dispersions of Dasatinib. Pharmaceutics. 2022;14:2450.","journal-title":"Pharmaceutics"},{"key":"3130_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.132074","volume":"269","author":"R Liu","year":"2024","unstructured":"Liu R, Hou W, Li J, Gou X, Gao M, Wang H, et al. Co-assembly of cisplatin and dasatinib in hyaluronan nanogel to combat triple negative breast cancer with reduced side effects. Int J Biol Macromol. 2024;269: 132074.","journal-title":"Int J Biol Macromol"},{"key":"3130_CR74","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1039\/D0BM01599G","volume":"9","author":"Q Li","year":"2021","unstructured":"Li Q, Yang X, Zhang P, Mo F, Si P, Kang X, et al. Dasatinib loaded nanostructured lipid carriers for effective treatment of corneal neovascularization. Biomater Sci. 2021;9:2571\u201383.","journal-title":"Biomater Sci"},{"key":"3130_CR75","doi-asserted-by":"publisher","first-page":"106112","DOI":"10.1016\/j.jddst.2024.106112","volume":"101","author":"KK Boddu","year":"2024","unstructured":"Boddu KK, Gubbiyappa KS. Multi-factor optimization and interaction analysis for enhanced nanobubble formulation and performance of Dasatinib. J Drug Deliv Sci Technol. 2024;101:106112.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3130_CR76","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s13318-024-00881-9","volume":"49","author":"M Raish","year":"2024","unstructured":"Raish M, Ahmad A, Karim BA, Jardan YAB, Ahad A, Iqbal M, et al. Pharmacokinetics of Dasatinib in Rats: a Potential Food-Drug Interaction with Naringenin. Eur J Drug Metab Pharmacokinet. 2024;49:239\u201347.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"3130_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/acsptsci.4c00492","volume":"8","author":"AG Chapdelaine","year":"2025","unstructured":"Chapdelaine AG, Sun G. Molecular Pharmacology of Dasatinib Provides Unique Insights into the Mechanistic Basis of Success and Failure of Targeted Cancer Therapy. ACS Pharmacol Transl Sci. 2025;8:1\u20139.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3130_CR78","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1080\/10717544.2022.2048132","volume":"29","author":"X Zeng","year":"2022","unstructured":"Zeng X, Zhang Y, Xu X, Chen Z, Ma L, Wang Y, et al. Construction of pH-sensitive targeted micelle system co-delivery with curcumin and dasatinib and evaluation of anti-liver cancer. Drug Deliv. 2022;29:792\u2013806.","journal-title":"Drug Deliv"},{"key":"3130_CR79","doi-asserted-by":"publisher","first-page":"113631","DOI":"10.1016\/j.colsurfb.2023.113631","volume":"233","author":"BN Saren","year":"2024","unstructured":"Saren BN, Mahajan S, Aalhate M, Kumar R, Chatterjee E, Maji I, et al. Fucoidan-mediated targeted delivery of dasatinib-loaded nanoparticles amplifies apoptosis and endows cytotoxic potential in triple-negative breast cancer. Colloids Surf B Biointerfaces. 2024;233:113631.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3130_CR80","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/1878-0261.13602","volume":"18","author":"C Marug\u00e1n","year":"2024","unstructured":"Marug\u00e1n C, Sanz-G\u00f3mez N, Ortigosa B, Monfort-Vengut A, Bertinetti C, Teijo A, et al. TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling. Mol Oncol. 2024;18:1531\u201351.","journal-title":"Mol Oncol"},{"key":"3130_CR81","doi-asserted-by":"publisher","first-page":"116474","DOI":"10.1016\/j.biopha.2024.116474","volume":"174","author":"L Wang","year":"2024","unstructured":"Wang L, Xiong B, Lu W, Cheng Y, Zhu J, Ai G, et al. Senolytic drugs dasatinib and quercetin combined with Carboplatin or Olaparib reduced the peritoneal and adipose tissue metastasis of ovarian cancer. Biomed Pharmacother. 2024;174:116474.","journal-title":"Biomed Pharmacother"},{"key":"3130_CR82","doi-asserted-by":"publisher","first-page":"124229","DOI":"10.1016\/j.jchromb.2024.124229","volume":"1243","author":"S Sen","year":"2024","unstructured":"Sen S, Ranjan OP. A Quality by Design (QbD) driven gradient high performance liquid chromatography method development for the simultaneous estimation of dasatinib and nilotinib in lipid nanocarriers. J Chromatogr B. 2024;1243:124229.","journal-title":"J Chromatogr B"},{"key":"3130_CR83","doi-asserted-by":"publisher","first-page":"120481","DOI":"10.1016\/j.biomaterials.2020.120481","volume":"267","author":"Y Liu","year":"2021","unstructured":"Liu Y, Li L, Liu J, Yang M, Wang H, Chu X, et al. Biomineralization-inspired dasatinib nanodrug with sequential infiltration for effective solid tumor treatment. Biomaterials. 2021;267:120481.","journal-title":"Biomaterials"},{"key":"3130_CR84","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00894-021-04925-8","volume":"27","author":"KML Rocha","year":"2021","unstructured":"Rocha KML, Nascimento \u00c9CM, Martins JBL. Investigation on the interaction behavior of afatinib, dasatinib, and imatinib docked to the BCR-ABL protein. J Mol Model. 2021;27:309.","journal-title":"J Mol Model"},{"key":"3130_CR85","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1080\/10717544.2021.1905751","volume":"28","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zeng X, Wang H, Fan R, Hu Y, Hu X, et al. Dasatinib self-assembled nanoparticles decorated with hyaluronic acid for targeted treatment of tumors to overcome multidrug resistance. Drug Deliv. 2021;28:670\u20139.","journal-title":"Drug Deliv"},{"key":"3130_CR86","doi-asserted-by":"publisher","first-page":"100043","DOI":"10.1016\/j.onano.2022.100043","volume":"7","author":"ST Kumbhar","year":"2022","unstructured":"Kumbhar ST, Patil RY, Bhatia MS, Choudhari PB, Gaikwad VL. Synthesis and characterization of chitosan nanoparticles decorated with folate and loaded with dasatinib for targeting folate receptors in cancer cells. OpenNano. 2022;7:100043.","journal-title":"OpenNano"},{"key":"3130_CR87","doi-asserted-by":"publisher","first-page":"e14471","DOI":"10.1111\/jfbc.14471","volume":"46","author":"KS Alharbi","year":"2022","unstructured":"Alharbi KS, Afzal O, Altamimi ASA, Almalki WH, Kazmi I, Al-Abbasi FA, et al. A study of the molecular mechanism of quercetin and dasatinib combination as senolytic in alleviating age-related and kidney diseases. J Food Biochem. 2022;46:e14471.","journal-title":"J Food Biochem"},{"key":"3130_CR88","first-page":"14","volume":"18","author":"JA Altoham","year":"2024","unstructured":"Altoham JA, Abdalla AN, Abourehab MAS, Tulbah AS. Evaluating dasatinib nanocarrier: Physicochemical properties and cytotoxicity activity on cancer cells. Int J Health Sci. 2024;18:14\u201321.","journal-title":"Int J Health Sci"},{"key":"3130_CR89","doi-asserted-by":"publisher","first-page":"119642","DOI":"10.1016\/j.lfs.2021.119642","volume":"278","author":"B Foroughi-Nia","year":"2021","unstructured":"Foroughi-Nia B, Barar J, Memar MY, Aghanejad A, Davaran S. Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors. Life Sci. 2021;278:119642.","journal-title":"Life Sci"},{"key":"3130_CR90","doi-asserted-by":"publisher","unstructured":"Cheng F, Li Q, Cui Z, Hong M, Li W, Zhang Y. Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings. Front Oncol. 2023;13. Available from: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/https:\/\/doi.org\/10.3389\/fonc.2023.1146108\/full.  Cited 2025 Feb 10.","DOI":"10.3389\/fonc.2023.1146108\/full"},{"key":"3130_CR91","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/cncr.35317","volume":"130","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, et al. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 2024;130:2652\u20139.","journal-title":"Cancer"},{"key":"3130_CR92","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/17474086.2024.2343885","volume":"17","author":"Y Peng","year":"2024","unstructured":"Peng Y, Huang J, Yin J, Meng F, Cao Y, Huang L, et al. Frontline combination of dasatinib and low-intensity chemotherapy in adults with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Rev Hematol. 2024;17:173\u201380.","journal-title":"Expert Rev Hematol"},{"key":"3130_CR93","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/imm.13768","volume":"172","author":"F Li","year":"2024","unstructured":"Li F, Wang Z, Zheng D, Pang Z, Feng C, Ma Y, et al. NK92 cells and peripheral blood NK cells respond oppositely upon dasatinib treatment. Immunology. 2024;172:163\u201377.","journal-title":"Immunology"},{"key":"3130_CR94","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ygyno.2024.03.029","volume":"186","author":"RL Hollis","year":"2024","unstructured":"Hollis RL, Elliott R, Dawson JC, Ilenkovan N, Matthews RM, Stillie LJ, et al. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma. Gynecol Oncol. 2024;186:42\u201352.","journal-title":"Gynecol Oncol"},{"key":"3130_CR95","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1038\/s41375-023-02045-1","volume":"37","author":"J Hofmann","year":"2023","unstructured":"Hofmann J, Bart\u016fn\u011bk A, Hauser T, Sedmak G, Ber\u00e1nek J, Ry\u0161\u00e1nek P, et al. Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans. Leukemia. 2023;37:2486\u201392.","journal-title":"Leukemia"},{"key":"3130_CR96","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/00365521.2021.2022190","volume":"57","author":"K Yamauchi","year":"2022","unstructured":"Yamauchi K, Inaba T, Colvin HS, Sakakihara I, Yamamoto K, Izumikawa K, et al. Dasatinib-induced colitis: clinical, endoscopic and histological findings. Scand J Gastroenterol. 2022;57:449\u201356.","journal-title":"Scand J Gastroenterol"},{"key":"3130_CR97","doi-asserted-by":"crossref","unstructured":"Shaikh R, Bhattacharya S, Saoji SD. Development, optimization, and characterization of polymeric micelles to improve dasatinib oral bioavailability: Hep G2 cell cytotoxicity and in vivo pharmacokinetics for targeted liver cancer therapy. Heliyon. 2024;10. Available from: https:\/\/www.cell.com\/heliyon\/abstract\/S2405-8440(24)15663-0.  Cited 2025 Feb 6.","DOI":"10.1016\/j.heliyon.2024.e39632"},{"key":"3130_CR98","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/cpdd.1416","volume":"13","author":"H Lennern\u00e4s","year":"2024","unstructured":"Lennern\u00e4s H, Brisander M, Liljebris C, Jesson G, Andersson P. Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology Platform. Clin Pharmacol Drug Dev. 2024;13:985\u201399.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"3130_CR99","doi-asserted-by":"crossref","unstructured":"Reddy Adena SK, Matte KV, Kosuru R. FORMULATION, OPTIMIZATION, AND IN VITRO CHARACTERIZATION OF DASATINIB LOADED POLYMERIC NANOCARRIERS TO EXTEND THE RELEASE OF THE MODEL DRUG. Int J Appl Pharm. 2021;318\u201330.","DOI":"10.22159\/ijap.2021v13i5.41995"},{"key":"3130_CR100","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.clml.2023.10.005","volume":"24","author":"AJ Klink","year":"2024","unstructured":"Klink AJ, Keating SJ, Brokars J, Feinberg B, Jabbour E. Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2024;24:149\u201357.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3130_CR101","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.18632\/aging.205581","volume":"16","author":"E Lee","year":"2024","unstructured":"Lee E, Carreras-Gallo N, Lopez L, Turner L, Lin A, Mendez TL, et al. Exploring the effects of Dasatinib, Quercetin, and Fisetin on DNA methylation clocks: a longitudinal study on senolytic interventions. Aging. 2024;16:3088\u2013106.","journal-title":"Aging"},{"key":"3130_CR102","doi-asserted-by":"publisher","first-page":"104807","DOI":"10.1016\/j.jddst.2023.104807","volume":"87","author":"CA Lamey","year":"2023","unstructured":"Lamey CA, Moussa N, Helmy MW, Haroun M, Sabra SA. Simultaneous encapsulation of dasatinib and celecoxib into caseinate micelles towards improved in vivo anti-breast cancer efficacy with reduced drug toxicity. J Drug Deliv Sci Technol. 2023;87:104807.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3130_CR103","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/pharmaceutics15030736","volume":"15","author":"MR Donthi","year":"2023","unstructured":"Donthi MR, Saha RN, Singhvi G, Dubey SK. Dasatinib-Loaded Topical Nano-Emulgel for Rheumatoid Arthritis: Formulation Design and Optimization by QbD, In Vitro, Ex Vivo, and In Vivo Evaluation. Pharmaceutics. 2023;15:736.","journal-title":"Pharmaceutics"},{"key":"3130_CR104","doi-asserted-by":"publisher","unstructured":"Luo X, McAndrews KM, Kalluri R. Natural and Bioengineered Extracellular Vesicles in Diagnosis, Monitoring and Treatment of Cancer. ACS Nano. 2025; Available from: https:\/\/pubs.acs.org\/doi\/full\/https:\/\/doi.org\/10.1021\/acsnano.4c11630.  Cited 2025 Feb 6.","DOI":"10.1021\/acsnano.4c11630"},{"key":"3130_CR105","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/j.clml.2021.01.020","volume":"21","author":"H Shin","year":"2021","unstructured":"Shin H, Ha J-E, Zang DY, Kim S-H, Do YR, Lee WS, et al. Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2021;21:e521\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3130_CR106","doi-asserted-by":"publisher","first-page":"6538","DOI":"10.3390\/ijms22126538","volume":"22","author":"E Russo","year":"2021","unstructured":"Russo E, Spallarossa A, Tasso B, Villa C, Brullo C. Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective. Int J Mol Sci. 2021;22:6538.","journal-title":"Int J Mol Sci"},{"key":"3130_CR107","doi-asserted-by":"crossref","unstructured":"Summer M, Hussain ,Tauqeer, Ali ,Shaukat, Khan ,Rana Rashad Mahmood, Muhammad ,Gulzar, and Liaqat I. Exploring the underlying modes of organic nanoparticles in diagnosis, prevention, and treatment of cancer: a review from drug delivery to toxicity. Int J Polym Mater Polym Biomater. 2025;74:829\u201345.","DOI":"10.1080\/00914037.2024.2375337"},{"key":"3130_CR108","doi-asserted-by":"crossref","unstructured":"Greish K, Jasim ,Anfal, Parayath ,Neha, Abdelghany ,Sara, Alkhateeb ,Ali, Taurin ,Sebastien, et al. Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme. J Drug Target. 2018;26:692\u2013708.","DOI":"10.1080\/1061186X.2017.1419357"},{"key":"3130_CR109","doi-asserted-by":"crossref","unstructured":"Benezra M, Hambardzumyan D, Penate-Medina O, Veach DR, Pillarsetty N, Smith-Jones P, et al. Fluorine-labeled Dasatinib Nanoformulations as Targeted Molecular Imaging Probes in a PDGFB-driven Murine Glioblastoma Model. Neoplasia. 2012;14:1132-IN8.","DOI":"10.1593\/neo.121750"},{"key":"3130_CR110","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.colsurfb.2015.12.053","volume":"140","author":"Q Li","year":"2016","unstructured":"Li Q, Lai KL, Chan PS, Leung SC, Li HY, Fang Y, et al. Micellar delivery of dasatinib for the inhibition of pathologic cellular processes of the retinal pigment epithelium. Colloids Surf B Biointerfaces. 2016;140:278\u201386.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3130_CR111","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4155\/tde-2020-0029","volume":"11","author":"S Gorantla","year":"2020","unstructured":"Gorantla S, Singhvi G, Rapalli VK, Waghule T, Dubey SK, Saha RN. Targeted drug-delivery Systems in the Treatment of Rheumatoid Arthritis: Recent Advancement and Clinical Status. Ther Deliv. 2020;11:269\u201384.","journal-title":"Ther Deliv"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03130-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03130-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03130-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T13:02:45Z","timestamp":1751893365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03130-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":111,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["3130"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03130-7","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest statement"}}],"article-number":"131"}}